Headquarters
Denmark
Every company in the roster headquartered in Denmark.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
6 of 6 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Novo NordiskNVO · NYSE | 28 assets: 9 approved, 8 Ph 3, 5 Ph 2, 6 Ph 1 | amycretinPhase 3 · ObesityReliable signal | Dec 2026UBT251 · Phase 1 |
 H. LundbeckHLUN.B · Nasdaq Copenhagen | 10 assets: 7 approved, 2 Ph 3, 1 Ph 2 | BexicaserinPhase 3 · EpilepsyPartial signal | 31 Oct 2026Bexicaserin · Phase 3 |
 Zealand PharmaZEAL · Nasdaq Copenhagen | 5 assets: 3 Ph 3, 1 Ph 2, 1 Ph 1 | dasiglucagonPhase 3 · Type 2 DiabetesReliable signal | 8 Dec 2026survodutide · Phase 1 |
 GubraPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | GUB-UCN2Phase 1/2 · Obesity | Dec 2028GUB-UCN2 · Phase 1/2 |
 Antag TherapeuticsPrivate | 1 asset: 1 Ph 2 | AT-7687Phase 2 · Obesity | Feb 2027AT-7687 · Phase 2 |
 PharmacosmosPrivate | 1 asset: 1 approved | Approved assets only | 30 Apr 2027Ferric derisomaltose · Phase 3 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).